Literature DB >> 28408455

Cell Therapy Trials in Congenital Heart Disease.

Hidemasa Oh1.   

Abstract

Dramatic evolution in medical and catheter interventions and complex surgeries to treat children with congenital heart disease (CHD) has led to a growing number of patients with a multitude of long-term complications associated with morbidity and mortality. Heart failure in patients with hypoplastic left heart syndrome predicated by functional single ventricle lesions is associated with an increase in CHD prevalence and remains a significant challenge. Pathophysiological mechanisms contributing to the progression of CHD, including single ventricle lesions and dilated cardiomyopathy, and adult heart disease may inevitably differ. Although therapeutic options for advanced cardiac failure are restricted to heart transplantation or mechanical circulatory support, there is a strong impetus to develop novel therapeutic strategies. As lower vertebrates, such as the newt and zebrafish, have a remarkable ability to replace lost cardiac tissue, this intrinsic self-repair machinery at the early postnatal stage in mice was confirmed by partial ventricular resection. Although the underlying mechanistic insights might differ among the species, mammalian heart regeneration occurs even in humans, with the highest degree occurring in early childhood and gradually declining with age in adulthood, suggesting the advantage of stem cell therapy to ameliorate ventricular dysfunction in patients with CHD. Although effective clinical translation by a variety of stem cells in adult heart disease remains inconclusive with respect to the improvement of cardiac function, case reports and clinical trials based on stem cell therapies in patients with CHD may be invaluable for the next stage of therapeutic development. Dissecting the differential mechanisms underlying progressive ventricular dysfunction in children and adults may lead us to identify a novel regenerative therapy. Future regenerative technologies to treat patients with CHD are exciting prospects for heart regeneration in general practice.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  dilated cardiomyopathy; general practice; hypoplastic left heart syndrome; prevalence; stem cell

Mesh:

Year:  2017        PMID: 28408455     DOI: 10.1161/CIRCRESAHA.117.309697

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  9 in total

1.  A mechanistic roadmap for the clinical application of cardiac cell therapies.

Authors:  Eduardo Marbán
Journal:  Nat Biomed Eng       Date:  2018-06-11       Impact factor: 25.671

2.  The use of cardiac progenitor cells for transplantation in congenital heart disease and an innovative strategy for activating mitochondrial function in such cells.

Authors:  Jiro Abe; Yuma Yamada; Hideyoshi Harashima
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

3.  Heterogeneity of adult masseter muscle satellite cells with cardiomyocyte differentiation potential.

Authors:  Wei Huang; Jialiang Liang; Yuliang Feng; Zhanfeng Jia; Lin Jiang; Wenfeng Cai; Christian Paul; Jianguo G Gu; Peter J Stambrook; Ronald W Millard; Xiao-Lan Zhu; Ping Zhu; Yigang Wang
Journal:  Exp Cell Res       Date:  2018-05-26       Impact factor: 3.905

Review 4.  The current status and future of cardiac stem/progenitor cell therapy for congenital heart defects from diabetic pregnancy.

Authors:  Jianxiang Zhong; Shengbing Wang; Wei-Bin Shen; Sunjay Kaushal; Peixin Yang
Journal:  Pediatr Res       Date:  2017-11-15       Impact factor: 3.756

5.  Effects of Exercise Training in Postoperative Patients With Congenital Heart Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Cheng Xu; Xiaoqi Su; Siyu Ma; Yaqin Shu; Yuxi Zhang; Yuanli Hu; Xuming Mo
Journal:  J Am Heart Assoc       Date:  2020-02-19       Impact factor: 5.501

6.  New Aspects in the Diagnosis and Therapy of Fetal Hypoplastic Left Heart Syndrome.

Authors:  Oliver Graupner; Christian Enzensberger; Roland Axt-Fliedner
Journal:  Geburtshilfe Frauenheilkd       Date:  2019-08-12       Impact factor: 2.915

7.  Augmenting canonical Wnt signalling in therapeutically inert cells converts them into therapeutically potent exosome factories.

Authors:  Ahmed G E Ibrahim; Chang Li; Russel Rogers; Mario Fournier; Liang Li; Sharon D Vaturi; Travis Antes; Lizbeth Sanchez; Akbarshakh Akhmerov; Jennifer Johnson Moseley; Brooke Tobin; Luis Rodriguez-Borlado; Rachel R Smith; Linda Marbán; Eduardo Marbán
Journal:  Nat Biomed Eng       Date:  2019-08-26       Impact factor: 25.671

8.  Identification of reference genes for gene expression studies among different developmental stages of murine hearts.

Authors:  Jie Ren; Ningning Zhang; Xiangjie Li; Xiaogang Sun; Jiangping Song
Journal:  BMC Dev Biol       Date:  2021-09-08       Impact factor: 1.978

9.  Cardiovascular Development and Congenital Heart Disease Modeling in the Pig.

Authors:  George C Gabriel; William Devine; Bethany K Redel; Kristin M Whitworth; Melissa Samuel; Lee D Spate; Raissa F Cecil; Randall S Prather; Yijen Wu; Kevin D Wells; Cecilia W Lo
Journal:  J Am Heart Assoc       Date:  2021-07-03       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.